1.1.................... moves to amend H.F. No. 1881 as follows:
1.2Delete everything after the enacting clause and insert:

1.3    "Section 1. [116J.886] CITATION; REGENERATIVE MEDICINE
1.5Sections 116J.886 to 116J.8862 shall be known as the Regenerative Medicine
1.6Development Act to promote private sector investment in regenerative medicine to
1.7strengthen the state's economy, reduce the long-term costs related to treating debilitating
1.8illnesses, advance the regenerative medicine industry, and facilitate and expand clinical
1.9research opportunities in the State of Minnesota.

1.10    Sec. 2. [116J.8861] DEFINITIONS.
1.11    Subdivision 1. Definitions. For the purposes of sections 116J.886 to 116J.8862, the
1.12following terms have the meanings given them.
1.13    Subd. 2. Business development services. "Business development services"
1.14means business incubator services and services to facilitate access to existing publicly
1.15or privately financed grants, loans, or loan guarantees, and to support basic or applied
1.16research , development of therapies, and development of pharmacologies and treatments
1.17through preclinical or clinical trials.
1.18    Subd. 3. Commissioner. "Commissioner" means the commissioner of employment
1.19and economic development.
1.20    Subd. 4. Office. "Office" means the Office of Regenerative Medicine Development
1.21established under section 116J.8862.
1.22    Subd. 5. Regenerative medicine. "Regenerative medicine" means the process of
1.23creating or using living, functional tissue to augment, repair, replace or regenerate organs
1.24and tissue that have been damaged by disease, injury, aging or other biological processes
.1.25    Subd. 6. Regenerative medicine development project or project. "Regenerative
1.26medicine development project" or "project" means any research, product development,
2.1or commercial venture relating to basic, preclinical, or clinical work to produce a drug,
2.2biological or chemical material, compound, or medical device designed to augment,
2.3repair, replace, or regenerate organs and tissue that have been damaged by disease, injury,
2.4aging or other biological processes.

2.7    Subdivision 1. Established. The commissioner shall establish an Office of
2.8Regenerative Medicine Development to provide business development services and
2.9outreach to promote and expand the regenerative medicine industry in Minnesota.
2.10    Subd. 2. Consultation. The office must regularly consult with external stakeholders,
2.11and must conduct public meetings to gather input. For the purposes of this section external
2.12stakeholders must include:
2.13(1) the director of the Minnesota Stem Cell Institute at the University of Minnesota;
2.14(2) a representative of a Minnesota based trade association with the largest number
2.15of bioscience companies as its membership;
2.16(3) a representative of a Minnesota based trade association with the largest number
2.17of hospitals as its membership; and
2.18(4) a representative of the largest private entity in Minnesota conducting research
2.19into the benefits and uses of regenerative medicine.
2.20    Subd. 3. Outside funding. The commissioner, on behalf of the office, may accept
2.21appropriations, gifts, grants, and bequests.
2.22    Subd. 4. Public infrastructure grant program. The commissioner shall coordinate
2.23the services and activities of the office with the innovative business development public
2.24infrastructure program under section 116J.435.
2.25    Subd. 5. Fiscal planning . By December 15, 2014, the commissioner shall develop
2.26a long-term budget proposal for the office for fiscal years 2016 through 2024 to provide
2.27business development services to regenerative medicine development projects.
2.28    Subd. 6. Project applications; selection. (a) The office shall provide business
2.29development services to eligible regenerative medicine development projects approved by
2.30the commissioner. To be eligible for business development services under this section, a
2.31regenerative medicine development project must:
2.32(1) demonstrate that at least 70 percent of the project costs are paid from nonstate
2.33sources. The nonstate share may include federal funds and the prior purchase of scientific
2.34equipment and materials incidental to the project, provided the purchase is completed not
2.35more than two years prior to the approval of funding by the commissioner;
3.1(2) not duplicate or supplant any other research or other project already conducted
3.2by the federal government, or for which federal funding is available; and
3.3(3) demonstrate that project activities are carried out directly by the grant recipient.
3.4(b) The commissioner shall establish an application and process for approving
3.5projects. Project applications must include the following information:
3.6(i) evidence that the required match is available and committed;
3.7(ii) a detailed estimate, along with necessary supporting evidence, of the total cost
3.8of the project;
3.9(iii) an assessment of the potential to attract new or continue existing public and
3.10private research grant awards resulting from the project;
3.11(iv) a detailed risk analysis projecting the likelihood of clinical success resulting in
3.12revenues or royalty payments from the project;
3.13(v) an assessment of the likelihood for and potential costs savings for publicly
3.14funded health care and long-term care programs from the project as a result of reducing
3.15the incidence or lowering the treatment costs of debilitating illnesses and diseases over
3.16the next ten years;
3.17(vi) a timeline indicating the major milestones of research projects and their
3.18anticipated completion dates, including any previously completed similar research; and
3.19(vii) an estimate of any potential current and future employment opportunities
3.20within the state, stimulation of economic growth, and the possibility for advancing the
3.21development of commercially successful and affordable regenerative medicine products,
3.22processes, or services. The application requirements are not in priority order and the
3.23commissioner may weigh each item, depending upon the facts and circumstances, as
3.24the commissioner considers appropriate.
3.25    Subd. 7. Report. The commissioner, on behalf of the office, must report to the
3.26legislative chairs with jurisdiction over economic development by January 1 of each
3.27odd-numbered year on successful economic development projects implemented or
3.28initiated since their last report and on plans for the upcoming year.
3.29    Subd. 8. Sunset. The office established under this section expires on June 30, 2024.

3.30    Sec. 4. APPROPRIATION.
3.31$450,000 in fiscal year 2015 is appropriated from the general fund to the
3.32commissioner of employment and economic development for the purposes of sections 1
3.33to 3."
3.34Amend the title accordingly